NCT02684357 - BI 655066 Versus Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis | Biotech Hunter

Enrollment

577

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

December 31, 2016

Study Completion Date

September 30, 2017

Conditions

Psoriasis

Interventions

DRUG

risankizumab

Risankizumab pre-filled syringe, administered by subcutaneous (SC) injection

DRUG

ustekinumab

Ustekinumab pre-filled syringe, administered by subcutaneous (SC) injection

DRUG

placebo for risankizumab

Placebo for risankizumab pre-filled syringe, administered by subcutaneous (SC) injection

DRUG

placebo for ustekinumab

Placebo for ustekinumab pre-filled syringe, administered by subcutaneous (SC) injection